Mark Pollack to Antidepressive Agents, Second-Generation
This is a "connection" page, showing publications Mark Pollack has written about Antidepressive Agents, Second-Generation.
Connection Strength
1.428
-
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007; 24(1):1-14.
Score: 0.282
-
Treatment of panic disorder: focus on paroxetine. Psychopharmacol Bull. 2003; 37 Suppl 1:53-63.
Score: 0.214
-
Citalopram for social phobia: a clinical case series. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Oct; 25(7):1469-74.
Score: 0.196
-
Nefazodone for social phobia: a clinical case series. Depress Anxiety. 1998; 8(3):131-3.
Score: 0.151
-
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry. 1997 Dec; 9(4):241-5.
Score: 0.150
-
Treatment of dysphoric mania with nefazodone. Am J Psychiatry. 1996 May; 153(5):732-3.
Score: 0.135
-
Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996; 32(4):667-70.
Score: 0.131
-
Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depress Anxiety. 2008; 25(2):167-71.
Score: 0.076
-
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000 Jun; 157(6):968-74.
Score: 0.045
-
Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry. 1999 Mar; 174:213-8.
Score: 0.041
-
Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress Anxiety. 1996-1997; 4(5):240-2.
Score: 0.008